rs7696472

This is a upstream gene variant variant in the UGT2B15 gene.

GWAS Catalog Trait Associations (5)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

testosterone measurement

Allele A
OR 0.04
p 2.0e-39
N 194,453
Large GWAS
European
Allele A
OR 0.14
p 2.0e-16
N 148,248
Major Consortium StudyLarge GWAS
European

vanillylmandelate (VMA) measurement

Allele A
OR 0.22
p 2.0e-26
N 6,136
Large GWAS
European

X-13729 measurement

Allele A
OR 0.07
p 1.0e-11
N 14,296
Large GWAS
European

hypogonadism

Allele G
OR 0.05
p 2.0e-8
N 145,389
Major Consortium StudyLarge GWAS
multi-ancestry

sex hormone-binding globulin measurement

Allele A
OR 0.02
p 2.0e-9
N 196,901
Large GWAS
European
Allele A
OR 0.01
p 5.0e-8
N 188,908
Large GWAS
European

Research that mentions this SNP (1)

Allelic imbalance (AI) identifies novel tissue-specificcis-regulatory variation for humanUGT2B15
FunctionalN=112Chang Sun et al.(2010)· Human Mutation

This functional study identifies cis-regulatory variants controlling UGT2B15 expression through allelic imbalance analysis. The coding variant rs1902023 (D85Y) shows allele-specific expression in liver but not breast tissue. Reporter assays confirm that two promoter SNPs (rs34010522 and rs35513228) regulate expression with ~20% activity difference in liver (P<0.001), and ChIP assays show rs34010522 lies within an Nrf2 transcription factor binding site.

Traits studied:Oxazepam glucuronidationUGT2B15 gene expression

About UGT2B15

This gene encodes a glycosyltransferase that is invovled in the metabolism and elimination of toxic compounts, both endogenous and of xenobiotic origin. This gene plays a role in the regulation of estrogens and androgens. This locus is present in a cluster of similar genes and pseudogenes on chromosome 4. [provided by RefSeq, Aug 2016]

View all UGT2B15 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…